TLDR SMMT traded near $11.70 premarket Monday, down about 17% to a new 52-week low. The FDA issued a Complete Response Letter for ivonescimab in EGFR-mutated lung cancer. The agency wants pro
TLDR
- SMMT traded near $11.70 premarket Monday, down about 17% to a new 52-week low.
- The FDA issued a Complete Response Letter for ivonescimab in EGFR-mutated lung cancer.
- The agency wants proof of an overall survival benefit that clears the statistical bar.
- Jefferies sees limited downside, and Barclays cut its target to $18 from $20.
- Summit says its commitment to ivonescimab has not changed.
Summit Therapeutics (SMMT) stock was trading near $11.70 in premarket action on Monday, down about 17%. That marks a fresh 52-week low.
Summit Therapeutics Inc., SMMT
The drop followed a letter the FDA sent on Sunday. The agency said it cannot approve the ivonescimab application in its current form.
The filing paired ivonescimab with platinum-based chemotherapy. It targeted advanced non-small cell lung cancer in patients who had already tried an EGFR inhibitor.
At this price, the stock sits roughly 60% below its 52-week high of $29.23. The listed 52-week low is $12.07, so Summit is now at the floor of its yearly range.
Why the FDA Said No
The FDA ruled that Summit did not show enough proof the drug works. It pointed to the lack of a statistically proven overall survival gain.
Slowing tumor growth was not enough on its own, the agency said. It wants to see that patients live longer.
The HARMONi trial did hit its progression-free survival goal. Overall survival showed a positive trend but missed the statistical bar.
Summit noted that no approved treatment in this setting has proven an overall survival benefit. A later look at Western patients with longer follow-up gave a hazard ratio of 0.76.
That 0.76 result held for the full group, Asian patients and Western patients alike. Safety was not the sticking point.
The company reported no new safety signals. Discontinuation and death rates were similar in both trial arms.
What Comes Next
Summit says its commitment to ivonescimab is unchanged. It points to five positive Phase III studies run by Summit and partner Akeso.
Jefferies called the rejection the base case and sees limited downside. The firm says second-line EGFR was never the core of the thesis, and it flags HARMONi-3 squamous data around year-end 2026 as the key event.
Barclays kept an Equalweight rating on the stock. It cut its price target to $18 from $20.
The Nasdaq fell 0.91% on Friday, and tech weakness carried into the new week. Summit’s drop landed on top of that.
No regulator in Summit’s license territories, including the U.S. and Europe, has approved ivonescimab. China cleared it in May 2024.
Akeso issued a notice on Monday about abnormal stock price swings. It came after Summit announced the FDA letter on Sunday.
The post Summit Therapeutics (SMMT) Stock Hits 52-Week Low After FDA Rejects Lung Cancer Drug appeared first on Blockonomi.